Journal
PSYCHOPHARMACOLOGY
Volume 183, Issue 1, Pages 92-102Publisher
SPRINGER
DOI: 10.1007/s00213-005-0154-9
Keywords
ketamine; N-methyl-D-aspartate; NMDA; schizophrenia; verbal fluency; executive function; functional magnetic resonance imaging; fMRI
Categories
Funding
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
Rationale: Glutamatergic dysfunction at N-methyl-D-aspartate (NMDA) receptors has been proposed as a neurochemical model for schizophrenia. A key feature of this disorder is impairments in cognitive function. Objective: The present study sought to investigate the effects of ketamine, an NMDA antagonist, on the performance and neural correlates of verbal fluency, a task that engages executive function. Methods: Ten healthy dextral male volunteers received intravenous placebo normal saline or ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg), administered in a double-blind, randomized order, during two functional magnetic resonance imaging sessions. During scanning, subjects performed a verbal fluency task. Two levels of cognitive load were examined in the task, and overt responses were acquired in order to measure subject performance on-line. Results: Ketamine induced symptoms in the healthy individuals comparable to an acute psychotic state. Although ketamine did not significantly impair task performance relative to placebo, an interaction of task demand with ketamine was observed in the anterior cingulate, prefrontal, and striatal regions. Conclusions: The behavioural and functional effects of ketamine during verbal fluency in healthy individuals were comparable to those evident in patients with schizophrenia. The findings support a role for glutamatergic dysfunction in the pathophysiology of schizophrenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available